AI-Powered
Pharmaceutical Intelligence
Access to drugs, clinical trials, patents, literatures and news in one search
Try:
AL-102 (Ayala)Crohn DiseasePneumococcal InfectionsFGFRL1APOC3Pfizer Inc.
104
K
Drugs & Biologics
46
K
Targets
1
M
Organizations
968
K
/
211
K
Clinical Trials / Results
67
M
Literatures
16
M
Patents
Recent blog posts
Monte Rosa Therapeutics and Novartis Ink Global Deal for VAV1-Targeted Therapies
Latest Hotspot
3 min read
Monte Rosa Therapeutics and Novartis Ink Global Deal for VAV1-Targeted Therapies
30 October 2024
Monte Rosa Therapeutics has signed a worldwide licensing deal with Novartis to promote VAV1-targeted molecular glue degraders that modulate T and B cells.
Read →
Merck and Moderna Launch Phase 3 Trial for V940 and KEYTRUDA® in Specific NSCLC Cases Post-Chemotherapy
Latest Hotspot
3 min read
Merck and Moderna Launch Phase 3 Trial for V940 and KEYTRUDA® in Specific NSCLC Cases Post-Chemotherapy
30 October 2024
Merck and Moderna have begun a Phase 3 study to assess V940 (mRNA-4157) with KEYTRUDA® (pembrolizumab).
Read →
Mirikizumab: First IL23p19 Antagonist with Long-Term Data in Ulcerative Colitis and Crohn’s Disease
Latest Hotspot
3 min read
Mirikizumab: First IL23p19 Antagonist with Long-Term Data in Ulcerative Colitis and Crohn’s Disease
30 October 2024
Lilly’s mirikizumab is the first and only IL23p19 antagonist to provide long-term safety and efficacy data over several years for ulcerative colitis and Crohn’s disease.
Read →
Check out our latest report
Roche's Bispecific Antibody Drug Emicizumab Patent Research and Practical Operation Guide

Roche's Bispecific Antibody Drug Emicizumab Patent Research and Practical Operation Guide

Emicizumab (Hemlibra) is a bispecific antibody developed by Roche that targets coagulation factors IXa and X. It was first approved by the FDA in November 2017 and received an expanded indication in 2018 for the prophylactic treatment of bleeding in hemophilia A patients, regardless of inhibitor status. This bispecific therapeutic is currently the only bispecific antibody drug used in the field of hemophilia. Since its market launch, Emicizumab has experienced a compound annual growth rate exceeding 300%, with sales surpassing $2 billion by 2020, thus becoming a blockbuster drug. In 2023, Hemlibra reported sales of CHF 4.147 billion (approximately $4.575 billion), reflecting a 16% year-over-year growth. The growth trajectory continues into 2024, with first-half sales reaching CHF 2.143 billion (approximately $2.529 billion). Sales are projected to reach $6.203 billion by 2028. As the highest-grossing bispecific antibody drug currently on the market, Emicizumab's patent landscape garners significant interest. This report aims to guide readers through a step-by-step patent analysis of the Emicizumab drug, ultimately providing a detailed patent landscape map. This can serve as a reference and provide insights for patent strategy in the bispecific antibody field.

GPRC5D Target Patent Research Report

GPRC5D Target Patent Research Report

Multiple myeloma (MM) is a stubborn disease that remains incurable. In recent years, targeted therapies against B-cell maturation antigen (BCMA) have shown promising responses in a substantial number of treated patients. However, the global relapse rate among myeloma patients following anti-BCMA treatment strategies is on the rise. This necessitates continuous exploration of therapies with novel mechanisms of action and new targets, one of which is the G protein-coupled receptor family C group 5 member D (GPRC5D). Due to its unique expression in the plasma cell lineage of MM patients, along with positive data from targeted chimeric antigen receptor T cells (CAR-T) and bispecific antibodies (BsAb), GPRC5D has emerged as an ideal target for anti-myeloma antibodies. The latest "GPRC5D Target Patent Research Report" from Patsnap Lifescience offers an in-depth analysis of global R&D trends related to the GPRC5D target. The report indicates that besides the already marketed Talquetamab, there are 38 drugs currently in clinical or preclinical stages. The R&D trends and market prospects of these drugs are poised to be critical to the future of MM treatment. In terms of patent coverage, the GPRC5D target enjoys a long protection period, providing development companies with prolonged R&D incentives and market exclusivity. The report not only covers the core patent status of approved drugs but also estimates the patent protection periods for clinical stage drugs, offering significant references for R&D decision-making within the industry. Additionally, the report highlights the exploration of combination therapies involving GPRC5D-targeted drugs and their potential applications in other plasma cell disorders, thus providing new perspectives for the future direction of MM treatment. As more companies invest in the development of innovative drugs targeting GPRC5D, we believe this target will offer more treatment options and hope to MM patients.

Global Drug R&D Express (Aug 2024)

Global Drug R&D Express (Aug 2024)

This report compiles and summarizes the basic information of all the first-to-market and special review drugs globally for the month of August totaling 124 drugs. Among them, 1 first-to-market drugs and 1 drugs under special review were selected for detailed analysis. The report provides an in-depth interpretation of these drugs, covering various aspects such as basic information, development status, technological barriers, mechanism of action, clinical trials, and competitive landscape.

Who We Serve
01
R&D Decision Makers
R&D Decision Makers
We provide R&D decision makers with access to accurate, connected data so they can quickly understand newly-emerged technology trends, have an insight into the competitive landscapes, uncover partnership opportunities, and decide the direction of innovation.
02
Business Development Professionals
Business Development Professionals
We provide 320,000+ life science organizations with drug pipeline and investment history, which help you make informed decisions on potential partnerships or acquisition targets.
03
Pharmaceutical Analyst
Pharmaceutical Analyst
We accelerate the research process for Pharmaceutical Analysts through various connected data, including drug approval, clinical trials, patent, non-patent literature and news. Synapse provides users with a 360-degree view of the competitive and technology landscape!
Get started for free today!
Access to drugs, clinical trials, patents, literatures and news in one search.